PAVANELLO, CHIARA
 Distribuzione geografica
Continente #
EU - Europa 7.038
NA - Nord America 6.163
AS - Asia 6.061
SA - Sud America 653
AF - Africa 194
OC - Oceania 102
Continente sconosciuto - Info sul continente non disponibili 8
Totale 20.219
Nazione #
US - Stati Uniti d'America 5.778
IT - Italia 2.232
CN - Cina 1.797
SG - Singapore 1.578
GB - Regno Unito 1.479
DE - Germania 967
HK - Hong Kong 497
BD - Bangladesh 448
BR - Brasile 430
FR - Francia 370
VN - Vietnam 362
RU - Federazione Russa 323
IN - India 300
SE - Svezia 270
JP - Giappone 267
CA - Canada 219
NL - Olanda 214
ES - Italia 198
IE - Irlanda 181
TR - Turchia 151
FI - Finlandia 138
ID - Indonesia 127
DK - Danimarca 107
MX - Messico 107
AU - Australia 91
TW - Taiwan 91
KR - Corea 90
PL - Polonia 87
AT - Austria 79
AR - Argentina 61
CH - Svizzera 53
UA - Ucraina 52
CO - Colombia 51
CI - Costa d'Avorio 47
ZA - Sudafrica 47
BE - Belgio 46
SA - Arabia Saudita 46
CL - Cile 40
GR - Grecia 37
IR - Iran 36
TH - Thailandia 34
RO - Romania 33
MY - Malesia 32
JO - Giordania 31
HU - Ungheria 30
IQ - Iraq 29
PT - Portogallo 26
CZ - Repubblica Ceca 23
EG - Egitto 23
PK - Pakistan 23
PH - Filippine 21
VE - Venezuela 21
AE - Emirati Arabi Uniti 18
TN - Tunisia 18
IL - Israele 16
RS - Serbia 16
EC - Ecuador 15
CR - Costa Rica 14
MA - Marocco 13
PE - Perù 13
UZ - Uzbekistan 13
HN - Honduras 11
QA - Qatar 11
HR - Croazia 10
NZ - Nuova Zelanda 10
BO - Bolivia 9
BG - Bulgaria 8
ET - Etiopia 8
NO - Norvegia 8
SC - Seychelles 8
SI - Slovenia 8
BH - Bahrain 7
LV - Lettonia 7
PY - Paraguay 7
SK - Slovacchia (Repubblica Slovacca) 7
KE - Kenya 6
LT - Lituania 6
PR - Porto Rico 6
SV - El Salvador 6
UY - Uruguay 6
GH - Ghana 5
JM - Giamaica 5
MT - Malta 5
AZ - Azerbaigian 4
BB - Barbados 4
DZ - Algeria 4
LB - Libano 4
LK - Sri Lanka 4
PS - Palestinian Territory 4
BY - Bielorussia 3
EE - Estonia 3
EU - Europa 3
IS - Islanda 3
KW - Kuwait 3
LU - Lussemburgo 3
NP - Nepal 3
OM - Oman 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
Totale 20.176
Città #
Southend 1.068
Singapore 942
Ashburn 648
Milan 605
Hong Kong 409
San Jose 338
Dallas 326
Frankfurt am Main 320
Hanover 283
Beijing 246
Chandler 236
Fairfield 224
Council Bluffs 199
Redwood City 191
Santa Clara 179
Los Angeles 170
Wilmington 168
New York 165
Seattle 158
Dublin 156
Houston 151
Rome 150
Hefei 145
Woodbridge 125
Ho Chi Minh City 112
Ann Arbor 108
Princeton 99
Cambridge 98
Istanbul 90
Bengaluru 86
Guangzhou 86
Helsinki 86
Shanghai 86
Jakarta 84
Nanjing 84
Dearborn 82
Hanoi 82
Lauterbourg 82
Tokyo 77
Buffalo 71
Toronto 67
Turin 65
Taipei 61
Grafing 56
São Paulo 54
Boardman 53
Munich 53
Abidjan 47
Moscow 46
Fuzhou 45
Naples 44
Chicago 42
London 39
Genoa 38
Jinan 36
Palermo 36
Paris 36
Des Moines 35
Phoenix 35
Vienna 34
Shenyang 32
Madrid 31
Tianjin 31
Berlin 30
Shenzhen 30
Amman 29
Bologna 29
San Diego 29
Seoul 29
The Dalles 29
Barcelona 28
Montreal 28
Warsaw 28
Cangzhou 27
Hangzhou 27
Philadelphia 26
Washington 26
Buenos Aires 24
Changsha 24
Mumbai 24
Nuremberg 24
Zhengzhou 24
Amsterdam 23
Athens 23
Bogotá 22
Delhi 22
Orem 21
San Francisco 21
Bangkok 20
Bari 19
Da Nang 19
Padova 19
Sydney 19
Ankara 18
Brooklyn 18
Florence 18
Ningbo 18
Santiago 18
Cape Town 17
Columbus 17
Totale 10.898
Nome #
Effect of soy on metabolic syndrome and cardiovascular risk factors : a randomized controlled trial 1.808
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 962
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study 937
Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study 834
LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters 614
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 535
A proteomic approach to identify novel disease biomarkers in LCAT deficiency 454
Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients 450
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 430
The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL 430
Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract : results from a randomized, double-blind, placebo-controlled study 403
Influence of body variables in the development of metabolic syndrome : A long term follow-up study 363
GENETIC LCAT DEFICIENCY AND ATHEROSCLEROSIS: STUDIES ON ENDOTHELIAL CELLS AND MONOCYTES 310
Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting : the PROSISA Study 310
Valutazione dei benefici salutistici dell'assunzione dI proteine della soia in pazienti con moderata sindrome metabolica 296
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 292
Systematic Lab Knowledge Integration for Management of Lipid Excess in High-Risk Patients : Rationale and Design of the SKIM LEAN Project 270
Evaluation of the health benefits of soy protein consumption in patients carrying the metabolic syndrome 264
Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients : a randomised controlled trial 260
Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study) 260
Nutraceutical approach to moderate cardiometabolic risk : results of a randomized, double-blind and crossover study with Armolipid Plus 254
Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation 245
The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency 244
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes : evidence in NAFLD patients and cell cultures 241
Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels 233
Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer's disease 232
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos) 227
Dysfunctional HDL as a therapeutic target for atherosclerosis prevention 220
Progression of chronic kidney disease in Familial LCAT Deficiency: a follow-up of the Italian cohort 219
Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation 199
Metformin: From diabetes to cancer to prolongation of life 199
Triglyceride-glucose index: carotid intima-media thickness and cardiovascular risk in a European population 193
Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis 192
Considering gender in prescribing statins : what do physicians need to know? 185
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia 184
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 184
HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD) 180
Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production 177
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH) : a cross-national retrospective survey 176
Autosomal recessive hypercholesterolemia : long-term cardiovascular outcomes 172
Apolipoprotein E isoforms differentially affect LCAT-dependent cholesterol esterification 170
Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open label interventional study 169
CA-IMT and QT parameters in dyslipidemic patients in primary prevention at different ESC/EAS cardiovascular risk levels 169
Novel therapeutic strategies for the homozygous familial hypercholesterolemia 166
Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group 164
Plasma FA composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans 162
Abnormal Lipoproteins Trigger Oxidative Stress-Mediated Apoptosis of Renal Cells in LCAT Deficiency 160
Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency 157
Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention 153
Cardiovascular determinants of QT interval duration in dysplipidemic patients in primary prevention in two genders 153
Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study 152
HDL-replacement therapy: From traditional to emerging clinical applications 150
Exploiting routine laboratory test to identify primary severe hypertriglyceridaemic patients in a large Italian hospital 149
Genetic and phenotypic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: two novel mutations 149
Nutraceutical approaches to metabolic syndrome 146
Appropriateness of statin prescription in the elderly 146
Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice 142
Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features 141
Genetic characterization of LDL-receptor in patients with a clinical diagnosis of familial hypercholesterolemia: two novel mutations 139
Soya-enriched mixed diet significantly improves cardiovascular and metabolic risk factors : A randomized controlled trial 139
Evaluation of high-density lipoprotein-bound long non-coding RNAs in subjects with familial hypercholesterolaemia 138
The relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype with preclinical atherosclerosis 138
HDL and chronic kidney disease 138
Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020 135
Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults 134
Plasma lipoproteins of patients with genetic LAL deficiency are enriched in cholesteryl esters: Relevance of cholesterol esterification by LCAT 132
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study 131
Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry 130
Spring Meeting of the Young Researchers of SID, SIIA, SIMI, SIPREC, SISA 130
Clinical implementation of bempedoic acid in blood lipid management: real-world data from an italian lipid clinic 129
Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National Lipigen Registry 129
Flipped C-Terminal Ends of apoA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs 129
Microsomal transfer protein (MTP) inhibition : a novel approach to the treatment of homozygous hypercholesterolemia 128
Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiency 122
Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning 122
Lipoprotein (a) : concentration, isoforms, polymorphisms and association with preclinical atherosclerosis 120
High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis 118
Emerging Therapies for Familial Lecithin-Cholesterol Acyltransferase Deficiency: A Role for Plasma Exchange 113
Gender-specific comparison of six QT correction formulae in dyslipidemic patients in primary prevention 113
Familial LCAT deficiency and cardiovascular disease: the game is not over. A case of dramatic multivessel atherosclerosis 109
Three new italian cases of LCAT deficiency 107
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia : Results of a Real-World Clinical Experience in Italy 105
Spring Meeting of the Young Researchers of SID, SIGG, SIIA, SIMI, SIPREC, SISA 91
Response to treatment and occurrence of cardiovascular (CV) complications in patients with autosomal recessive hypercholesterolemia (ARH): A retrospective analysis 79
Lipidome of high-density lipoprotein is strongly perturbed in hyperalphalipoproteinemia resulting from a rare mutation in endothelial lipase 69
Cerebrospinal fluid CEFA composition is enriched in saturated fatty acids and it is altered in Alzheimer's Disease 68
Bempedoic acid does not affect skeletal muscle mitochondrial activity in apoE-/- mice 48
LDL-C target achievement after adding evinacumab in 2 patients with autosomal recessive hypercholesterolemia 46
Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound 22
Impact of bempedoic acid on skeletal muscle mitochondrial activity in ApoE-/- mice – a preliminary analysis 22
Cholesterol in amyotrophic lateral sclerosis: a bystander, a biomarker, or a target? 1
Totale 20.910
Categoria #
all - tutte 53.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.174


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.595 104 109 117 156 129 159 115 109 159 139 113 186
2022/20231.877 123 119 105 102 169 229 143 174 232 126 207 148
2023/20241.876 168 187 191 243 305 94 89 114 66 92 161 166
2024/20252.988 125 267 110 254 233 156 156 292 228 315 302 550
2025/20267.326 597 472 750 562 614 390 859 302 686 542 849 703
2026/2027240 240 0 0 0 0 0 0 0 0 0 0 0
Totale 20.910